Eli Lilly, the manufacturer of the drug Zyprexa, may face more legal troubles after the FDA told the company it would delay the approval of its new drug Symbyax for hard-to-treat depression because the agency wanted more information about the risk of diabetes in the medicine’s prescribing label. Symbyax combines Lilly’s antipsychotic pill Zyprexa and the antidepressant Prozac. Zyprexa has already been shown to cause diabetes and pancreatitis. The company has come under heavy criticism for failing to disclose dangerous and often fatal side effects such as
fever, stiff muscles, confusion, sweating, fast or irregular heartbeats, spasmodic muscular movements, sudden headaches, problems with vision, speech or balance, hallucinations, and increased thirst and frequent urination.
For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.
Admitted to practice law in all federal multidistrict litigation courts, the California State Bar and the Florida Bar. His philosophy is to provide aggressive, quality representations and seek fair compensation for individuals and their families who have suffered injury, death, or sexual abuse.
Comments for this article are closed.